Solid state characterization of mometasone furoate anhydrous and monohydrate forms

Journal of Pharmaceutical Sciences

Volumn 94, Issue 11, 2005, Pages 2496-2509

  Chen, Xiaoming ^a   Carillo, Matthew ^a   Haltiwanger, R Curtis ^b   Bradley, Prudence ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRUKER AXS INC   (United States)

Author keywords

Anhydrous form; Crystal structure; Hydration; Mometasone furoate; Monohydrate; Physical characterization; Solid state

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; MOMETASONE FUROATE; WATER;

ARTICLE; CRYSTALLIZATION; DRUG ADSORPTION; DRUG FORMULATION; ENVIRONMENTAL TEMPERATURE; HEATING; INFRARED SPECTROSCOPY; MOISTURE; TEMPERATURE DEPENDENCE; THERMAL ANALYSIS; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

EID: 30544435804     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20470     Document Type: Article

References (18)

1. Puar MS, Thompson PA, Ruggeri M, Beiner D, McPhail AT. 1995. An unusual rearrangement product formed during production of mometasone furoate (Sch 32088). Steroids 60:612-614.
2. Davies RJ, Nelson HS. 1997. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clini Ther 19:27-38.
3. Prakash A, Benfield P. 1998. Topical mometasone: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 55:145-163.
4. Onrust SV, Lamb HM. 1998. Mometasone furoate: A review of its intranasal use in allergic rhinitis. Drugs 56:725-745.
5. Berkowitz RB, Bernstein DI, LaForce C, Pedinoff AJ, Rooklin AR, Damaraju CRV, Mesarina-Wicki B, Nolop KB. 1999. Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis. Allergy 54:64-69.
6. Sharpe M, Jarvis B. 2001. Inhaled mometasone furoate: A review of its use in adults and adolescents with persistent asthma. Drugs 61:1325-1350.
7. Byrn SR, Pfeiffer RP, Stowell JG. 1999. Solid-state chemistry of drugs, 2nd Edition. West Lafayette, Indiana: SSCI, Inc.
8. Yuen PH, Eckhart C, Etlinger T, Levine N. 1992. Preparation and formulation of stable crystalline mometasone furoate monohydrate. PCT Int Appl 18: WO 9204365.
9. Shapiro EL, Gentles MJ, Tiberi RL, Popper TL, Berkenkopf J, Lutsky B, Watnick AS. 1987. 17-Heteroaroyl esters of corticosteroids. 2. 11β-hydroxy series. J Med Chem 30:1581-1588.
10. Morris KR. 1999. Structural aspects of hydrates and solvates. In: Polymorphism in pharmaceutical solids. New York: Marcel Dekker, Inc. 125-181.
11. Brittain HG, Bugay DE, Bogdanowich SJ, DeVincentis J. 1988. Spectral methods for determination of water. Drug Dev Ind Pharm 14:2029-2046.
12. Byrn SR, Lin CT. 1976. The effect of crystal packing and defects on desolvation of hydrate crystals of caffeine and L-(-)-1,4-cyclohexandiene-1- alanine. J Am Chem Soc 98:4004-4005.
13. Lin CT, Byrn SR. 1979. Desolvations of solvated organic crystals. Mol Cryst Liq Cryst 50:99-104.
14. Gerdil R. 1961. The crystal structure of thymine monohydrate. Acta Crystallogr 14:333-344.
15. Zhu H, Padden BE, Munson EJ, Grant DJW. 1997. Physicochemical characterization of nedocromil bivalent metal salt hydrates. 2. Nedocromil zinc. J Pharm Sci 86:418-429.
16. Bettinetti G, Mura P, Sorrenti M, Faucci MT, Negri A. 1999. Physical characterization of picotamide monohydrate and anhydrous picotamide. J Pharm Sci 88:1133-1139.
17. Ledwidge MT, Draper SM, Wilcock DJ, Corrigan OI. 1996. Physicochemical characterization of diclofenac N-(2-hydroxyethyl)pyrrolidine: Anhydrate and dihydrate crystalline forms. J Pharm Sci 85:16-21.
18. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. Mikrochimica Acta 2:273-316.